Eton Pharmaceuticals Valuation
| ETON Stock | USD 14.41 0.13 0.91% |
At this time, the firm appears to be overvalued. Eton Pharmaceuticals shows a prevailing Real Value of $11.86 per share. The current price of the firm is $14.41. Our model computes the value of Eton Pharmaceuticals from reviewing the firm fundamentals such as Shares Outstanding of 25.84 M, profit margin of (0.21) %, and Current Valuation of 356.53 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Eton Pharmaceuticals' valuation include:
Price Book 23.3112 | Enterprise Value | Enterprise Value Ebitda 51.2617 | Price Sales 11.8548 | Forward PE 37.594 |
Overvalued
Today
Please note that Eton Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Eton Pharmaceuticals is based on 3 months time horizon. Increasing Eton Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Eton Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eton Stock. However, Eton Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.41 | Real 11.86 | Target 13.0 | Hype 14.11 |
The intrinsic value of Eton Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Eton Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Eton Pharmaceuticals helps investors to forecast how Eton stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eton Pharmaceuticals more accurately as focusing exclusively on Eton Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Eton Pharmaceuticals' intrinsic value based on its ongoing forecasts of Eton Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Eton Pharmaceuticals' closest peers.
Eton Pharmaceuticals Cash |
|
Eton Valuation Trend
Knowing Eton Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Eton Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Eton Revenue by Product
Eton Pharmaceuticals Total Value Analysis
Eton Pharmaceuticals is currently estimated to have valuation of 356.53 M with market capitalization of 236.92 M, debt of 5.4 M, and cash on hands of 17.05 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Eton Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
356.53 M | 236.92 M | 5.4 M | 17.05 M |
Eton Pharmaceuticals Investor Information
About 33.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.26. Eton Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Eton Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Eton Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Eton Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Eton Pharmaceuticals has an asset utilization ratio of 99.69 percent. This suggests that the Company is making $1.0 for each dollar of assets. An increasing asset utilization means that Eton Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Eton Pharmaceuticals Ownership Allocation
Eton Pharmaceuticals holds a total of 25.84 Million outstanding shares. 30% of Eton Pharmaceuticals outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Eton Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 31.64 M. Net Loss for the year was (936 K) with profit before overhead, payroll, taxes, and interest of 14.32 M.About Eton Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Eton Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Eton Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Eton Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Eton Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Eton Pharmaceuticals. We calculate exposure to Eton Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Eton Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 24.2 M | 25.4 M | |
| Pretax Profit Margin | (0.02) | (0.02) | |
| Operating Profit Margin | (0.03) | (0.04) | |
| Net Loss | (0.03) | (0.03) | |
| Gross Profit Margin | 0.60 | 0.63 |
Eton Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 25.6 M | |
| Quarterly Earnings Growth Y O Y | -0.126 | |
| Forward Price Earnings | 37.594 |
Eton Pharmaceuticals Current Valuation Indicators
Eton Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Eton Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Eton Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Eton Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Eton Pharmaceuticals' worth.When determining whether Eton Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eton Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eton Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eton Pharmaceuticals Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets |
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.